Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis on track for the third quarter of 2025.

In April 2025, our partner Jazz announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of ...

AI Proteins, a biotechnology company pioneering the development of de novo designed miniprotein therapeutics, will be sending four key scientists to present at PEGS Boston 2025, the leading ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...

Trailhead Biosystems Inc. ( a biotechnology company advancing human cell innovation, has secured $20 million in financing. Trailhead specializes in precisely differentiating induced pluripotent stem ...

Six posters presented at the American Association for Cancer Research (AACR) annual meetingAppointment of Dr. Sabeen Mekan as Senior Vice President, Clinical DevelopmentReported $321.6 million in cash ...

Thank you for standing by, and welcome to the Krystal Biotech First Quarter 2025 Earnings Call. At this time, all participants are on a listen-only mode. After the speakers' presentations, there will ...

Data cutoff date for Phase 2b NAVIGATE trial efficacy reached on April 30, 2025; top-line data readout expected in late June ...

In this week's newsletter, also read about Shivangi Singh's flight path from fighter jets to space, Blue Jet Healthcare ...

Mecbotamab vedotin (Mec-V; CAB-AXL-ADC) continues to demonstrate exceptional overall survival (OS) with a 2-year landmark ...

Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ETCompany ParticipantsBill Szablewski - Head of Capital MarketsScott Smith ...